Invex Therapuetics
Following is my rationale for investing in Invex therapeutics
Focused on repurposing Exenatide for neurological conditions involving raised intracranial pressure such as idiopathic intracranial hypertension(IIH) Assignment of intellectual property from University of Birmingham, United Kingdom.
Dr Alexandra Sinclair is a founder of Invex and proposed CSO and Executive Director clinician and global leader in the pathophysiology of idiopathic intracranial hypertension and headache, with over 10 years research in this field.
IPO to raise a minimum of $A10 and up to a maximum of $A12 million to fund the proposed later stage research and development programme .
Completed proof of concept preclinical invitro data published in world leading scientific journal .
Orphan Drug Designations granted for IIH in Europe (EMA) and in the US (FDA)
Phase II proof of concept clinical study initiated in IIH
Lower development risk Faster commercialisation strategy
Established lower cost business model Worldclass scientific and management team
Management :
Dr Jason Loveridge - Non-Executive Chairman Dr Loveridge is a founder of Invex and currently CEO of 4SC AG, a Frankfurt (Germany) listed oncology company. He has more than thirty years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has substantial transactional experience in the sale and partnering of biotechnology assets. Dr Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia, and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia. He is also a fellow of the Royal Society of Medicine. The Board considers that Dr Loveridge is not an independent Director.
Dr Alexandra J Sinclair - Proposed Executive Director and Chief Scientific Officer Dr Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK. Dr Sinclair is a fellow of the British Medical Association, UK, the Association of British Neurologists, UK, the Royal College of Physicians, London, the Society for Endocrinology, the International Headache Society, the British Association of the Study of Headache, UK, the North American Neuro-ophthalmology Society and the European Headache Federation.
Directors are taking very modest remuneration of $35000 to $70000 pa ( Unlike other biotechs /medtechs where scientific staffs take millions of dollars salaries/fees)
Directors and founding shareholders have committed more than $A 2.5 million in seed capital and investment at IPO
23.75 mil out of 25 mil existing shares are escrowed for 12 to 24 months. Extremely tight capital structure and assuming register will be very tight as well.
Forrest capital is a lead manager of this IPO who did CYP IME etc . Forrest capital is one of best Biotech/medtech lead manager.
It was very hard to get ANY allocations and I was told book is done and dusted.
Being loyal CPS client , I managed to get some and will top up post listing .
Decent Biotech/Medtech IPOs and stocks are doing extremely well i.e. EX1 EMV NXS ( Disclosure: I am holding all 3 from IPO ) which bodes very well for Invex .
I hope it won't double at listing So that we can top up more under 30 mil EV ( 80c SP ) but I think there is a fair chance that it will open double.
ALL IMO
DYOR
GLTAH
Expand
